GSK3 polypeptides
AssigneeChiron Corporation
InventorsStephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
Life of this patent
Estimating the term…
Loading patent…
AssigneeChiron Corporation
InventorsStephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
Estimating the term…
The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
An isolated nucleic acid comprising a polynucleotide encoding a polypeptide consisting essentially of SEQ ID NO:2, wherein said polypeptide will crystallize and will have at least one biological activity selected from the group consisting of (a) binding a GSK3 inhibitor;
An isolated nucleic acid comprising a polynucleotide encoding a polypeptide consisting essentially of SEQ ID NO:3, wherein said polypeptide will crystallize and will have at least one biological activity selected from the group consisting of (a) binding a GSK3 inhibitor;
A polypeptide comprising between about 250 and 419 contiguous amino acids of SEQ ID NO:1, wherein said polypeptide is phosphorylated on tyrosine 216, said polypeptide will crystallize, and said polypeptide will have at least one biological activity selected from the group consisting of (a) binding a GSK3 inhibitor;
A polypeptide consisting essentially of between about 278 and 419 contiguous amino acids of SEQ ID NO:1, wherein said polypeptide exhibits at least 1% of the kinase activity of human GSK3β.
A polypeptide consisting essentially of between about 285 and 384 contiguous amino acids of SEQ ID NO:1, wherein said polypeptide exhibits at least 1% of the kinase activity of human GSK3β.
A polypeptide consisting essentially of between about 351 and 384 contiguous amino acids of SEQ ID NO:1, wherein said polypeptide exhibits at least 1% of the kinase activity of human GSK3β.
A polypeptide consisting of the amino acid sequence of SEQ ID NO:2.
A polypeptide consisting of the amino acid sequence of SEQ ID NO:3.
An isolated nucleic acid comprising a polynucleotide encoding a polypeptide consisting essentially of SEQ ID NO:5, wherein said polypeptide will crystallize and will have at least one biological activity selected from the group consisting of (a) binding to a GSK3 inhibitor;
A polypeptide comprising between about 182 and 482 contiguous amino acids of SEQ ID NO:4, wherein said polypeptide will crystallize, and said polypeptide will have at least one biological activity selected from the group consisting of (a) binding a GSK3 inhibitor;
A polypeptide consisting essentially of between about 182 and 386 contiguous amino acids of SEQ ID NO:4, wherein said polypeptide exhibits at least 1% of the kinase activity of human GSK3α.
A polypeptide consisting essentially of between about 182 and 351 contiguous amino acids of SEQ ID NO:4, wherein said polypeptide exhibits at least 1% of the kinase activity of human GSK3α.
A polypeptide consisting essentially of contiguous amino acids S97 to S447 of SEQ ID NO:
A polypeptide consisting essentially of the amino acid sequence of SEQ ID NO:5.
A polynucleotide encoding a polypeptide consisting essentially of SEQ ID NO:6.
A polypeptide consisting essentially of the amino acid sequence of SEQ ID NO:6.
A polynucleotide encoding a polypeptide consisting essentially of SEQ ID NO:7.
A polypeptide consisting essentially of the amino acid sequence of SEQ ID NO:7.
A polynucleotide encoding a non-phosphorylated human GSK3 polypeptide, wherein said non-phosphorylated polypeptide differs from native GSK3 in at least one and not more than ten amino acids.
Dependencies are inferred from the claim text.